
Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
"I can always find a couple of biotech stocks to smoke," Shkreli said in a livestream.
以下正文同步自 Ars Technica,版权归原站所有,已转换为易读排版。
Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and getting a seven-year prison sentence for the fraudulent scheme he used to do it—has been under a lifetime ban from the pharmaceutical industry since 2022. However, according to the Federal Trade Commission and the attorneys general of seven states, Shkreli has "flagrantly and repeatedly" violated that ban nearly the entire time—allegedly by trading stock in dozens of drug companies and discussing the industry during livestreams on social media. On Tuesday, the FTC and the seven states asked a federal judge to hold Shkreli in contempt for the alleged violations. The states include New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same states that joined the FTC in suing Shkreli in 2020 over the "elaborate anticompetitive scheme" involving the anti-parasitic drug, Daraprim. The scheme raised the price from $17.50 per pill to $750 per pill virtually overnight, while blocking generic competitors from entering the market. Read full article Comments
正文由 探How 从来源站点 RSS 同步,内容未经改写;遇到排版缺失或需要图片、视频时请以原文为准。